Loading clinical trials...
Loading clinical trials...
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psor...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Sun Pharmaceutical Industries, Inc.
NCT05969223 · Genital Psoriasis, Scalp Psoriasis
NCT01195831 · Scalp Psoriasis
NCT01083758 · Scalp Psoriasis
NCT06015152 · Scalp Psoriasis
NCT00400725 · Scalp Psoriasis
Taro Pharmaceuticals USA Inc.
Hawthorne, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions